Skip to content
NeuroTechGuide

Blue Arbor Technologies raises $10.5 million in an Ottobock-led round for nerve-controlled prosthetics

The Michigan company plans to finish feasibility studies, seek FDA permission for US clinical studies and begin developing a fully implantable version of its RESTORE system.

In briefFundingImplants

Blue Arbor Technologies closed a $10.5 million Series A led by prosthetics maker Ottobock, its strategic partner, the company said on October 28. Its RESTORE system connects the peripheral nervous system to a robotic prosthetic limb and is designed to give independent, simultaneous control of the fingers, wrist and elbow. The money will go toward feasibility studies, an FDA Investigational Device Exemption for US studies of an external sensing unit, and early work on a fully implantable unit.

Blue Arbor reports two human implantations so far, including one at the Medical University of Vienna. RESTORE holds FDA Breakthrough Device Designation but remains investigational and is not approved for commercial use anywhere.

Learn more: Neuroprosthetics · Breakthrough Device Designation · Ottobock

Share:XLinkedInBlueskyEmail

More news